Clinical trial
Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III…
NCT00310154 · Wake Forest University Health Sciences, Other · Completed
Key facts
| NCT number | NCT00310154 |
|---|---|
| Title | Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer |
| Official title | ZD-1839 (Iressa®) With Concurrent Docetaxel and Conformal Three Dimensional Thoracic Radiation Followed by Consolidative Docetaxel and ZD-1839 for Patients With Stage III Non Small Cell Lung Cancer: A Phase I Study |
| Lead sponsor | Wake Forest University Health Sciences, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug, Other, Radiation |
| Interventions | docetaxel, gefitinib, laboratory biomarker analysis, radiation therapy |
| Enrollment | 45 |
| Start date | Nov 1, 2003 |
| Primary completion | Jul 1, 2007 |
| Completion | Aug 1, 2010 |
| First posted | Apr 3, 2006 |
| Last update posted | May 30, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: